Lilly Invests in Virginia to Expand U.S. Manufacturing and Advance Next-Generation Medicines

Lilly’s new state-of-the-art facility in Goochland County will strengthen America’s biopharmaceutical manufacturing capabilities and create economic opportunities for workers and communities across the state.

Lilly announced plans to invest in a new, cutting-edge manufacturing facility in Goochland County, Virginia. The site will support the production of next-generation medicines — including treatments for cancer and other serious diseases — while creating 650 high-quality jobs and 1,800 construction jobs. The new facility represents Lilly’s first fully integrated active pharmaceutical ingredient and drug product plant, designed to advance its growing pipeline of innovative biologic medicines.

With strong support from Virginia’s government, this investment highlights the power of collaboration and private-public partnership to drive economic growth. “For every dollar they spend, it will contribute four dollars into the community,” Virginia Governor Glenn Youngkin said, emphasizing the ripple effects Lilly’s investment will have on Virginia’s economy, businesses, universities and communities. This campus is one of four new U.S. manufacturing sites Lilly is planning to build, reflecting a $50 billion capital commitment since 2020 and an ongoing focus on ensuring lifesaving medicines are discovered, developed and manufactured in America.

By expanding its U.S. manufacturing footprint, Lilly is deepening its commitment to patients, innovation and the American workforce, delivering the future of medicine while driving economic opportunity.z